Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors

Immunohistochemical landscape of AT/RT tissue

First, we analyzed an independent cohort of n=17 AT/RT tissues for the prevalence of T cells, HLA and PD-L1 molecules. Diagnosis of AT/RT was confirmed by central neuropathological review in all cases. 1.8 ± 5.1 % of all cells within AT/RT tissues represented CD3⁺ T cells. HLA class I and to a lesser degree also class II molecules were found to be expressed on tumor cells. PD-L1 expression level on tumor cells was 5.1 ± 6.8% as determined by the Cologne scoring system (Fig. 1 A+B). Linear regression revealed a weak inverse correlation between HLA class I and CD3 expression (Fig. 1C) and positive correlation between HLA class I and PD-L1 (Fig. 1D). From one of the freshly obtained tumor samples we were able to create a primary rhabdoid cell line. On this cell line we could confirm constitutive expression of HLA class I and IFNγ-inducible upregulation of HLA class II and PD-L1 molecules (Fig. 1E).

• Download figure
• Open in new tab

Fig. 1. Immunohistochemistry of AT/RT tissues.

n=17 AT/RT tissues were evaluated for expression of CD3, HLA-ABC, HLA-DR, and PD-L1 on tumor cells. (A) Mean values ± standard deviations for all four markers, 10 visual fields were evaluated in each tumor sample. (B) Representative examples for each of the four markers. (C and D) Linear regression analysis of HLA-ABC expression against CD3⁺ T-cell infiltration (C) and PD-L1 expression (D). (E) Flow cytometric analysis of one primary rhabdoid cell line. Shaded line represents unstained control, blue line constitutive expression, red line expression after IFNγ stimulation of tumor cell line.

LC-MS/MS-based immunopeptidome profiling reveals AT/RT-associated HLA source proteins and HLA class I and II ligands eligible for immunotherapy approaches

23 AT/RT tumor samples could be retrieved from 5 tumor cell banks throughout Germany with a centrally confirmed diagnosis of an AT/RT. The cohort included a total of 51 different HLA class I allotypes, HLA-A*03:01 (n = 9) being the most frequent, followed by HLA-A*02:01 (n = 6), HLA-C*04:01 (n = 6), and HLA-C*07:01 (n = 6, figure S2). Among the world’s population, 99.9% of individuals carry at least one HLA class I allotype that is represented within the here analyzed AT/RT cohort (figure S2) (15, 16). The comparative cohort of benign tissue donors showed an HLA allotype population coverage of 99.8% (figure S2) and matched 100% of HLA-A allotypes (13/13), 72% of HLA-B allotypes (13/18), and 92% of HLA-C allotypes (11/12) of the AT/RT cohort.

LC-MS/MS analysis of these 23 AT/RT tumor samples identified 7,628 unique HLA class I peptides (range 13-1,372, mean 459 per sample) (Figure 2A) from 4,807 source proteins at a local PSM-level FDR of 5%. The in-house HLA class I benign cohort contained 282 tissues covering among others brain (n = 5) and cerebellum (n = 5) (HLA Ligand Atlas Paper Version 2017, extended with ligandomes from disease-free ovary). Based on these two datasets, we performed comparative HLA class I ligandome profiling to identify AT/RT-associated source proteins (Figure 2 B). We identified 55 HLA class I source proteins exclusively presented on AT/RT samples and from these 56 distinct HLA class I peptide ligands as candidates for downstream immunogenicity analysis (Figure 2B, table S1). The majority of AT/RT-associated source proteins (48/55) were individual to each AT/RT tumor, while only six were shared between two patients, and one was shared between tumor and ascites sample of the same patient.

• Download figure
• Open in new tab

Fig. 2. HLA Class I and II Peptide Identifications

(A) Number of identified peptides in each tumor sample for HLA class I (upward columns) and class II (downward colums). Grey vs. black shading illustrates predicted or non-predicted binding of peptides to self-HLA allotypes in the respective patients. Red squares (right y-axis) show purity of peptide pools, i.e. the ratio of predicted binding vs. total number of identified peptides. (B) Waterfall plot demonstrating overall source protein identifications for HLA class I ligands (x-axis) in benign (green, downward columns) and AT/RT tissue (blue, upward columns) and their frequency in the respective patient cohort. Tumor-exclusive are only the source proteins in the far left red boxes which have no corresponding counterpart in any benign tissue (red parts of Venn diagrams). (C) Same illustration for HLA class II source proteins.

With respect to HLA class II, 30 distinct class II allotypes were identified in the AT/RT patient cohort, with HLA-DQB1*03:01 (n = 27) being the most frequent, followed by HLA-DRB1*03:01 (n = 20) and HLA-DRB1*15:01 (n = 20). Among the world’s population, 99,7% of individuals carry at least one HLA class II allotype encompassed in the AT/RT cohort, with an average hit number of 3.71 per individual (figure S2).

LC-MS/MS analysis of the AT/RT HLA ligandome revealed 3,827 distinct HLA class II peptide sequences (range: 9 – 698, mean per sample 214) (Figure 2A) originating from 1,517 source proteins at 5% local PSM-level FDR. Our HLA class II benign cohort entails 132 ligandomes from benign samples, covering among other tissues, 5 cerebellum and 5 brain samples. Unfortunately, most benign HLA class II ligandomes lack HLA class II typing. By comparing the AT/RT and benign tissue cohort regarding single mapped source proteins, we were able to identify 139 AT/RT-associated HLA class II source proteins associated to 122 distinct HLA class II ligands (Figure 2C, table S1). Remarkably, multiple AT/RT-associated source proteins were shared among patients: one was presented in 8 different AT/RT samples, three additional source proteins were shared between four AT/RT patients and 11 were shared between two patients. As observed for HLA class I AT/RT-associated source proteins, the majority (124) was unique to each patient (Figure 2C).

Cryptic peptides in AT/RTs ligandome

Next, we extended our search to identify cryptic HLA class-I peptides from allegedly non-coding regions of the human genome. To this end, we applied a recently introduced approach (Peptide-PRISM) that combines de novo peptide sequencing, highly efficient string search, mixture modeling, and search space stratified filtering of the false discovery rate (FDR) (13). De novo sequencing was performed for all LC-MS/MS data of the 23 AT/RT tumors samples with PEAKS X. Peptide-PRISM was used to match all de novo sequencing candidates against the 3-frame translated human transcriptome and the 6-frame translated human genome. 209 cryptic peptides were identified (FDR 10%), 158 of which were predicted as binder (rank < 2%) to one of the corresponding patient HLA alleles by NetMHCpan 4.0. The distribution of the 158 cryptic peptides among the different categories is shown in Fig. 3A. The highest number of peptides derived from non-canonical ORFs close to the canonical translation start site (categories UTR5 and OffFrame). These cryptic peptides presumably originate from translational misinitiation. An example of such a peptide is shown in Fig. 3B.

• Download figure
• Open in new tab

Fig. 3. Identification of cryptic class I peptides.

158 class I peptides have been identified and predicted as binder to one of the corresponding patient alleles in AT/RT tumor samples. (A) Distribution of identified cryptic peptides among genomic categories. (B) Example of a cryptic HLA peptide from 5’-UTR. The peptide was identified in two AT/RT patients, but not in benign tissue. The peptide is predicted as a strong binder (rank < 0.5%) by NetMHCpan in both patients for HLA-B*51:01 and HLA-B*07:02, respectively. (C) Most frequently mutated proteins and their localization on the 23 chromosomes. Numbers in parentheses indicates the number of different mutations found in the respective protein.

In order to identify potentially tumor-associated or tumor-specific cryptic peptides, we filtered out all cryptic peptides that have previously been identified within the human HLA ligand atlas project (https://hla-ligand-atlas.org) (17). 61 of the 158 cryptic binding peptides were identified only in AT/RT tumor samples, but not in benign tissue (table S2). In addition, we compared the cryptic peptides identified in AT/RT samples with cryptic peptides previously identified in glioblastoma (GBM) tumor tissue, as well as plasma-soluble HLAs (18). A complete list of all cryptic peptides from these samples has been recently published (13). 20 of the 61 (33%) cryptic peptides have been recurrently identified in either at least two AT/RT patients (9/61, 15%) or AT/RT and GBM patients (11/61, 18%), e.g. the cryptic peptide LSLEEGIVEV derived from an intron of HIPK3 is identified recurrently in 5 AT/RT patients (table S2).

We selected six cryptic peptides from different categories for analyzing their immunogenicity (see below). Fragment ion spectra of these six synthetically preparated peptides were generated for validating the peptide identification. For all but one peptide (MPISLVQLL) comparison of the fragment ion spectra obtained from AT/RT samples with the fragment ion spectra of the corresponding synthetic peptide confirmed the initial peptide identification (figure S3).

Nonsynonymous mutations in AT/RTs

Furthermore, we were interested to examine whether the oncogenic SMARCB1 mutation can give rise to immunogenic peptides. After ligandome analysis, additional tissue was left in 18 cases, in 9 of these also PBMCs were available. In the cases with tumor tissue only, MPLA sequencing of the SMARCB1 locus was performed. In these assays, only homo-or heterozygous deletions but no SNVs of the SMARCB1 locus were detectable, making the existence of neoepitopes in this region unlikely (table S3). In the other nine AT/RT cases we isolated genomic DNA from fresh-frozen AT/RT tissues and corresponding PBMCs for whole-exome sequencing (WES). As expected, the overall number of non-synonymous mutations was low (median 16, range 1 – 155). Five tumors harbored ≤ 7 SNV, whereas four tumors displayed a higher number of SNVs (99, 112, 137, and 155). Two of these belonged to the SHH-, one each to the TYR-and MYC-group, respectively. Also in WES, no non-synonymous mutations in the SMARCB1 locus could be identified. The 24 most frequently mutated genes and their chromosomal location are shown in Figure 3C.

To identify potential neoantigenic epitopes from these SNVs, overlapping 9-mer peptide libraries moving the mutation from pos 1-9 were generated and analyzed for predicted binding to all HLA alleles of the individual patient. The peptide with the best binding score for any of the patients’ HLA alleles was selected. A complete list of all in silico predicted neoantigens is provided in table S4. None of these neoantigenic peptide sequences could be verified in the MS data.

Immunogenicity of ligandome peptides

To assess potential immunogenicity of all identified, AT/RT-associated HLA class I peptides, we first compared in silico predicted MHC binding affinity using NetMHCpan 4.0. Whereas binding affinity of neoantigenic and ligandome cryptic peptides was almost identical, ligandome-identified canonical class I peptides displayed a significantly higher binding affinity, suggesting that these peptides have undergone an in vivo selection process in the class I peptide loading complex (Fig. 4A).

• Download figure
• Open in new tab

Fig. 4. Immunogenicity of HLA class I peptides.

(A) Peptides sequences of natural and non-canonical HLA-ligands identified by MS as well as in silico predicted neoepitopes were ranked according to the NetMHCpan4.0 algorithm. The best binding HLA allele from each tumor sample was chosen. Pie charts below the graph show classification of %rank values into strong (≤0.5), weak (0.5-2) and non-binders (>2), n indicates the total number of peptides per group. (B) Peptides with an HLA-ligand listed in the IEDB data base were alternatively scored for immunogenicity according to the IEDB alogrithm, n indicates the number of peptides which could be submitted to the IEDB server. (C) Highly purified naïve CD8⁺ T cells from 5 healthy HLA-A*02:01 (n=4) and -B07*02 (n=1) positive donors were cocultured for 12 days with peptide-loaded autologous DCs in the presence of IL-7, -15, and -21, restimulated and assayed for IFNγ/TNFα production. A response 3x above background (empty DCs) was considered as positive (green bars), responses above background but not positive were defined as intermediate (grey bars). N indicates the total number of wells tested in the respective peptide group. Pseudo-color dot plots on the right side display three representative examples of positive responses for ligandome natural and cryptic peptides and neoantigenic epitopes, respectively. For the complete data set of priming assays please refer to fig. S3. Numbers in the upper right quadrant show percentages of CD8⁺IFNγ⁺, numbers in the upper left quadrant indicate number of positive experiments against the amount of donors tested. The bold and red colored amino acid indicates the mutation. P-values were determined using Mann-Whitney or Kruskal-Wallis test.

MHC-I binding algorithms mainly rely on binding of certain amino acids to anchor residues at P1, P2, and P9 of the MHC-I peptide binding groove. Recently, several in silico immunogenicity prediction tools have used alternative computational methods to assess T-cell receptor recognition of a peptide MHC complex, e.g. based on the presence of large, aromatic residues at P4, P5, and P6 of a peptide (IEDB database) or the hydrophobicity, molecular size and polarity of whole protein sequences (VaxiJen server). The IEDB database requires knowledge of the individual peptide sequence and only a limited set of validated HLA-alleles can be analyzed with this tool. For IEDB, we considered only peptides with the validated length of 9 amino acids. IEBD generally yielded lower frequencies of peptides with a positive prediction (37.8 – 52.3%) than the VaxiJen platform (62.3 – 77.9%). Using the IEDB prediction algorithm AT/RT ligandome class I peptides had higher immunogenicity prediction scores than neoantigenic peptide sequences (Fig. 4B). In contrast, the VaxiJen server favored neoantigenic and ligandome cryptic over ligandome class I source proteins (data not shown). There was no correlation between MHC binding affinity and either IEBD or VaxiJen scores (data not shown).

In addition to these in silico predictions, we tested the immunogenicity of the identified peptides in an in vitro priming assay. This assay uses highly-purified naïve CD8⁺ T cells from healthy donors as starting population and autologous DCs as stimulators, thereby closely mimicking a vaccination scenario in vivo (19, 20). We focused on two HLA-alleles with a high prevalence in our general population (HLA-A*02:01 and -B*07:02) and tested all identified peptides for binding to these two alleles. From the resulting strong binders we choose 12, 6, and 9 peptides from the list of ligandome-identified canonical class I, cryptic, and neoantigenic peptide pools, respectively. 92% (11 out of 12), 83% (5 out of 6), and 89% (8 out of 9) of the tested peptides yielded at least one positive well with no significant difference between the groups (Fig. 4C, the complete data set of priming assays is shown in fig. S4), confirming that the majority of peptides from the different pools can be recognized by naïve T cells.

Furthermore, we investigated whether memory responses against these peptides can be detected in AT/RT patients. PBMCs from 4 AT/RT patients were assayed in restimulation experiments for IFNγ-response against peptides fitting their HLA restrictions. For HLA class I peptides we screened all peptides for potential binding to HLA-A and -B alleles from these four patients and identified 17, 18, 23, and 32 suitable peptides for restimulation experiments. As demonstrated in Fig. 5A only one ligandome peptide (FPILSTILL from the CCG4 source protein) showed a positive response in one patient whereas all other experiments remained negative, confirming that constitutive CD8⁺ T-cell responses against tumor-associated peptides without prior vaccination are exceedingly rare. The same assay was repeated for the 18 HLA class II peptides which were identified more than once in AT/RT tumor samples with gating on CD3⁺CD4⁺ T cells (Fig. 5B). Notably, 15/18 class II peptides showed at least one positive response, 2 peptides even gave positive results in three out of four patients tested. To analyze whether these responses are specific for patients with AT/RT, we repeated this experiment with PBMCs from three high-grade glioma (HGG) patients and three healthy controls. In HGG patients, 10/18 peptides yielded a positive response, however, only in one patient each. The LSIEEDVLAA peptide derived from THMS1 source protein (detectable in 8 different AT/RT samples) showed a more substantial response in one HGG patient (Fig. 5B). In PBMCs from healthy controls only 8 faint responses at the detection limit in singular patients were measurable. These data indicate that T_helper cells of AT/RT patients have been exposed to HLA class II ligandome peptides before which has resulted in memory formation in more than 80% of tested peptides. This phenomenon seems to be tumor-specific as such responses were less detectable in HGG patients and virtually absent in healthy donors. For HLA class I peptides no such memory formation could be observed.

• Download figure
• Open in new tab

Fig. 5. Recall responses against HLA class I and class II peptides in AT/RT patients.

(A) Peptides sequences of natural and non-canonical HLA class I ligands identified by MS as well as in silico predicted neoepitopes were screened for binding to the HLA-A and -B alleles of 4 AT/RT patients, in whom PBMCs were available. The resulting 17, 18, 23, and 32 peptides were used to activate PBMCs from these 4 patients. Column graphs show frequencies of CD8⁺IFNγ⁺ T cells after 1-2 rounds of restimulation. Pie charts above source protein names display the frequency of positive tests (>3x above background, in yellow). Zebra plots below the charts show one representative example of the onliest positive result in a natural ligandome peptide and two negative wells from a cryptic and neoantigenic peptide from the same patient plus controls. (B) The 18 ligandome class II peptides which were detected in more than one tumor sample were used to activate CD4⁺ T cells from 4 AT/RT patients. PBMCs of three patients with high-grade gliomas and three healthy individuals served as controls. Column graphs show frequencies of CD4⁺IFNγ⁺ T cells after 1-2 rounds of restimulation. Pie charts above source protein names display the frequency of positive tests (>3x above background, in yellow). Zebra plots below the charts show five representative examples of positive responses to class II peptides from different AT/RT patients.

Gene ontology and protein network analysis

Having identified tumor-exclusive peptides from four different sources (ligandome HLA class I and II peptides from natural proteins, ligandome class I cryptic, and neoantigenic peptides) we mined these data for existing overlap between the respective source proteins or pathway enrichment. Functional annotation using the DAVID Bioinformatics database revealed little similarity in terms of biological process or molecular function (table S5). Of note, the four different peptide sources covered distinct cellular compartments. In line with previous reports, HLA class I ligandome peptides were mainly derived from cytosolic proteins, whereas HLA class II ligandome source proteins were allocated to the plasma membrane. AT/RT neoantigens covered external and internal membrane proteins (plasma, Golgi, endo-/lysosomal membranes, junctions, MHC class II complex), whereas source proteins of ligandome cryptic peptides were primarily assigned to the nucleoplasm (Fig. 6A). Functional enrichment analysis of protein networks showed 4, 3, and 1 enriched protein domains within neoantigenic, cryptic and HLA class I source proteins, respectively, whereas for HLA class II no such enrichment could be detected (Fig. 6B). Likewise, only the network of mutated proteins displayed a significantly higher number of interactions than expected, with a cluster in HLA-and HLA-associated genes (Fig. 6C), which is consistent with the high number of mutations on chromosome 6 (Fig. 3C). Taken together, these data indicate that source proteins from different AT/RT-specific peptide pools cover a wide variety of biological functions, and show little enrichment of particular protein domains. However, at least in AT/RTs, the different peptide sources seem to emerge from distinct cellular compartments.

• Download figure
• Open in new tab

Fig. 6. Gene ontology and network analysis of AT/RT peptides.

(A) Functional annotation “cellular compartment” of the four different AT/RT peptides sources defined by DAVID Bioinformatics Resources 6.8. (B) Listing of enriched protein domains in the four source protein cohorts. (C) Protein network analysis using STRING. (D) Overlap of the AT/RT peptide pool with four published cancer immunopeptidome data sets: GBM 1 (21), GBM2 (18), ovarian cancer (22) and renal cell carcinoma (23).

Overlap of AT/RT ligandome with other tumor-specific ligandomes

Finally, we matched our list of HLA class I AT/RT ligandome peptides from natural source proteins with published data sets of tumor-specific ligandomes from other cancer entities. Selection criterion for these comparators was their tumor-specificity, i.e. the exclusion of peptides also found in other benign tissues. We used two published data sets from glioblastoma (18, 21), and one from ovarian cancer (22) and renal cell carcinoma (23) each. While 6% of source proteins overlapped between the two GBM datasets, only 2% could be found simultaneously in AT/RT and GBM. No overlap existed between AT/RTs and the two non-CNS cancers (ovarian and renal, Fig. 6D). The more substantial overlap (33%) between AT/RT and GBM in the cryptic ligandome has been mentioned above.

Patients, tissues and blood samples

AT/RT tissue samples (n=18) were obtained from tumor banks at the University Hospitals in Würzburg, Bonn, Heidelberg, Berlin, and Tübingen. In n=5 patients treated in Tübingen and Würzburg, fresh tissue could be obtained directly from neurosurgical procedures. Informed consent from the guardians of the patients was obtained following internal regulations of the institutional review board (Ethics Commission at the Faculty of Medicine, University of Würzburg, #86/15). According to the requirements of the German HIT-Netzwerk, AT/RT diagnoses were centrally reviewed and confirmed in all 23 available cases by the DGNN reference neuropathology in Bonn. Tumour tissue samples have been snap frozen and stored in liquid nitrogen until usage. All samples were subject to ligandome analysis as described below. In n=10 cases, reference DNA from peripheral mononuclear cells was available, thus, in these cases whole exome sequencing and neoepitope identification could be performed. In 9 tumor samples, MPLA sequencing of the SMARCB1 locus was carried out to identify the nature of the SMARCB1 mutation. The whole workflow of AT/RT tissue workup is detailed in figure S1. For immunohistochemistry, n=17 additional formalin-fixed and paraffin-embedded (FFPE) AT/RT tumor tissues from the neuropathologies in Würzburg and München were used. Population coverage analysis for HLA class I and II was performed using the IEDB analysis resource (http://tools.iedb.org/population/)(15).

HLA typing

HLA alleles for loci A, B, C, DRB1 and DQB1 were determined by standard sequencing procedures (sequence-based typing SBT, Protrans GmbH, Hockenheim, Germany or GenDx, The Netherlands) which provide high resolution typing. Confirmatory typing was undertaken by sequence-specific oligonucleotides (SSO, One Lambda or Olrup CareDx, San Francisco, USA) according to institutional regulations.

Immunohistochemistry

Paraffin-embedded samples (thickness 2 µm) of n=17 AT/RT tissue were deparaffinized with Xylol and Ethanol and subsequently stained with standard immunohistochemistry procedures against CD3 (dilution 1:150), HLA class I (clone EMR 8-5, Abcam, dilution 1:1600), HLA class II (clone CR3/43, Abcam, dilution 1:1000), and PD-L1 (dilution 1:500). One day after primary antibody incubation, slides were stained with streptavidin-peroxidase-complex (BioGenex, Fremont CA, USA) for 10 min andd counterstained with Mayer’s hemalaun solution. Human tissue from tonsil (CD3, HLA class II), liver (HLA class I), and placenta (PD-L1) served as a positive control. Expression levels were evaluated semiquantitatively by two independent investigators and given as the frequency of positive cells per visual field. 10 visual fields per tumor were analyzed. For determining the PD-L1 expression level, the harmonized Cologne scoring system was used (47).

Isolation of HLA ligands

HLA class I and clas II molecules were isolated using standard immunoaffinity purification (48, 49). In brief, snap-frozen AT/RT tissue samples were minced in lysis buffer containing 10 mM CHAPS/PBS (AppliChem, St. Louis, MO, USA/Gibco, Carlsbad, CA, USA) and one protease inhibitor tablet (Complete; Roche, Basel, Switzerland). We employed the pan-HLA class I-specific antibody W6/32 (50) and the HLA-DR-specific antibody L243 (51), both produced in house (University of Tübingen, Department of Immunology) from HB-95, and HB-55 hybridoma cell lines (ATCC, Manassas, VA) respectively. Furthermore, the pan-HLA class II-antibody Tü39 was employed (52), and produced in house from a hybridoma clone previously described. Antibodies were covalently linked to to CNBr-activated Sepharose (GE Healthcare, Chalfont St Giles, UK). HLA molecules were purified by cyclically passing the cleared protein lysate from AT/RT tissue over two columns. The first column contained 1 mg of W6/32 antibody coupled to sepharose, whereas the second column contained equal amounts of Tü39 (0.5 mg) and L243 (0.5 mg) antibody coupled to sepharose HLA-DR1 is known to be expressed at higher levels than the other class II allotypes, therefore the specific L243 mAb at the given stoichiometry was used (53). Tü39 is utilized complementarily to pull-down the remaining class II complexes. HLA–peptide complexes were eluted by repeated addition of 0.2% TFA (trifluoroacetic acid, Merck, Whitehouse Station, NJ, USA). Eluted HLA ligands were purified by ultrafiltration using centrifugal filter units (Amicon; Millipore, Billerica, MA, USA) with 3 kDa and 10 kDa pore size for HLA class I and HLA class II ligands, respectively. HLA ligands were desalted using ZipTip C18 pipette tips (Millipore). Extracted peptides were eluted in 35 µl 32.5% acetonitrile (Merck)/0.2% TFA, and vacuum-centrifuged to 2 – 5 µl and resuspended in 25 µl of 1% acetonitrile/0.05% TFA. Samples were stored at −80 °C until analysis by LC–MS/MS.

Analysis of HLA ligands by LC-MS/MS

Peptide samples were separated by reversed-phase liquid chromatography (nano-UHPLC, UltiMate 3000 RSLCnano; Thermo Fisher, Waltham, MA, USA) and analyzed in online-coupled LTQ Orbitrap XL mass spectrometer (Thermo Fisher). Samples were analyzed in three or five technical replicates. Sample shares of 20% were trapped on a 75 µm × 2 cm trapping column (Acclaim PepMap RSLC; Thermo Fisher) at 4 µl/min for 5.75 min. Peptide separation was performed at 50 °C and a flow rate of 175 nl/min on a 50 µm × 25 cm separation column (Acclaim PepMap RSLC; Thermo Fisher) applying a gradient ranging from 2.4 to 32.0% of acetonitrile over the course of 90 min. Samples were analyzed on an LTQ Orbitrap XL using a top five CID (collision-induced dissociation) method with survey scans at 60k resolution and fragment ion detection in the ion trap (ITMS2) operated at normal scan speed. Fragmentation of HLA class I ligands was limited to precursors with a mass range of 400–650 m/z and charge states 2+ and 3+. For HLA class II ligands, a mass range of 300–1500 m/z with charge states ≥ 2 were selected for fragmentation.

Database search

The software Proteome Discoverer (v.1.3; Thermo Fisher) was used to perform database search using the Mascot search engine (Mascot 2.2.04; Matrix Science, London, UK). The human proteome as comprised in the Swiss-Prot database (http://www.uniprot.org, status September 2013, 20,225 reviewed sequences contained) was used as reference database. The search combined data of technical replicates and was not restricted by enzymatic specificity. Precursor mass tolerance was set to 5 ppm, and fragment mass tolerance to 0.5 Da. Oxidation of methionine residues was allowed as a dynamic modification. False discovery rate (FDR) estmation was performed using the Percolator node (54) and was set to a peptide spectrum match level FDR ≤ 5%. For HLA class I ligands, peptide lengths were limited to 8–12 amino acids (AA), for HLA class II, peptides were limited to 8–25 AA of length. Protein grouping was disabled, allowing all proteins that contain a given peptide to be annotated as peptide source proteins Only HLA class I ligands mapping into one source protein alone were considered for this analysis (3,244 potential targets). As a final step of quality control, binding prediction was performed employing NetMHC-3.0 with a cut-off score of % Rank<0.5 for strong binders and <2 for weak binders (55).

Whole genome DNA sequencing

Library preparation and whole genome sequencing of tumor and matching normal DNA from peripheral blood was carried out as described previously (56). Briefly, 1-5 µg of genomic DNA was fragmented to ~300 bp insert size using a Covaris device. Size selection was conducted by agarose gel excision. For Paired-end library preparation we used Illumina, Inc. v2 protocols. Sequencing was performed on HiSeq2000 machines at the German Cancer Research Center (DKFZ) Genomics and Proteomics Core Facility. Sequencing reads were mapped and aligned as describe (3). Briefly, we called variants using samtools and vcftools on the tumor bam files. The called positions were looked up in the control bam file and the resulting raw calls were filtered using different annotations and criteria to create a set of high confidence somatic SNVs. Indels were called using the pipeline platypus (57). All coordinates used in the analyses are based on human reference genome assembly hg19, GRCh37 (ncbi.nlm.nih.gov/assembly/ 2758). Gene annotations are based on genecode annotation release 19 (gencodegenes.org/releases/19.html). Whole Genome Sequencing data have been deposited at the European Genome-phenome Archive, EGA Study Accession IDEGAS00001001297.

The obtained mutated and the corresponding wildtype sequences were verified in Uniprot or Ensemble databases (https://www.uniprot.org/, http://apr2018.archive.ensembl.org/index.html). For each mutation a virtual 9mer-library was created moving the mutated amino acid from pos 1-9 and matched with the individual HLA class I type (HLA-ABC) on the NetMHCpan 4.0 server (http://www.cbs.dtu.dk/services/NetMHCpan). For each mutation the best binding peptide was selected according to binding affinity and %Rank.

Immunogenicity prediction tools

For in silico immunogenicity prediction two different online platforms were used. VaxiJen2.0 is a publicly available online platform which uses an alignment-independent method for vaccine subunit prediction based on auto cross covariance transformation (http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html). Amino acid properties (hydrophobicity, size and polarity) are transcribed in z descriptors independently from the corresponding HLA allele (58). Protein sequences of source proteins were entered in fasta format, and Tumour selected as target organism. As suggested before, we chose a threshold of 0.45 to define probable protective antigens, slightly higher sensitivity than initially proposed threshold of 0.5(23). In order to consider also HLA-restriction, we additionally chose the IEDB immunogenicity prediction tool (http://tools.iedb.org/immunogenicity) (59). Since the original validation of this algorithm was performed only for nonamer-peptides were restricted our analysis to 9-mers, and to the HLA-molecules specified in the menu. Peptide sequences of potential epitopes were entered, and the T-cell recognition score was determined with a threshold of 0.1 was set to distinguish whether HLA-ligands were predicted to be “immunogenic” or “non-immunogenic.” Additionally, the mean T-cell recognition score was calculated for ligandome class I, ligandome cryptic, and neoantigenic peptides in order to compare immunogenicity of these three distinctive groups. Furthermore, the frequencies of probably protective/immunogenic antigens was calculated for the whole group as well as for the subgroups of strong, weak, or non-binders according NetMHC alogithms.

Gene ontology and protein network analysis

Gene ontology and functional annotations of source proteins were defined and analyzed using DAVID Bioinformatics Resources 6.8, NIAID/NIH (https://david.ncifcrf.gov/summary.jsp) (60). Protein-protein interaction networks and functional enrichment analysis of proteins from different peptide sources was performed using STRING (https://string-db.org/cgi/input.pl)(61). For description of protein domains the PFAM 32.0 database was chosen (https://www.pfam.xfam.org). Overlap of ligandome source proteins was analyzed and visualized using the BioVenn web application (https://www.biovenn.nl) (62).

Naïve CD8⁺ T-cell priming and T-cell expansion protocol

For T-cell priming assays we used a previously described protocol (19, 20). In brief, naïve CD8⁺ T cells were isolated from the peripheral blood of healthy donors positive for HLA-A02*01 (n=4) or -B07*02 (n=1) using a purification of CD8⁺ events, followed by depletion with CD45RO and CD57 microbeads on LD and LS columns (Miltenyi, Bergisch Gladbach, Germany). Isolated naïve CD8⁺ T cells were incubated with IL-7 overnight. The next day, T cells were washed and mixed with irradiated, matured autologous DCs, pulsed with either the heteroclitic HLA-A02*01-restricted peptide Melan-A26-35L as a control or the investigational peptides as indicated at 1 µg/ml. IL-21 (30 ng/ml, Peprotech) was added to the co-culture on day 0 the next morning. IL-7 and IL-15 (5 ng/ml, Peprotech) were added on days 3, 5, and 7 and cells were harvested on day 10, some of them after restimulation with the original peptide. The Melan-A26-35L (ELAGIGILTV), and investigational peptides were purchased from jpt (Berlin, Germany). Harvested T-cells on day 10 or 12 were analyzed for TNFα/IFNγ-positivity. T-cell responses three times above the negative control (autologous DCs without peptide) were considered positive, those above the background but <3x were considered intermediate.

T-cell responses defined by specific IFNγ-secretion were measured using a stimulation-expansion-restimulation protocol (63): PBMCs were isolated by Ficoll, stimulated with mature, peptide-loaded autologous DCs at a 4:1 (T:DC) ratio and expanded subsequently with IL-15 (5 ng/ml) for 12–14 days. Medium and IL-15 was refreshed every second or third day. On days 7 and 14 PBMCs were restimulated with the same peptide loaded DCs. Negative control was stimulation with empty DCs (mature, autologous DCs without peptide loading). 6 h after the last restimulation, T cells were analyzed for IFNγ-production by intracellular cytokine staining. Only T-cell responses three times above the negative control (autologous DCs without peptide) were considered positive. In HLA class I assays, the CEF-pool peptide mix (jpt, Hamburg, Germany) was used as a positive control.

Identification of cryptic peptides

Cryptic HLA-I peptides were identified using Peptide-PRISM as described recently (13). De novo peptide sequencing was performed with PEAKS X (Bioinformatics Solutions Inc., Canada) (64). Raw data refinement was performed with the following settings: (i) Merge Options: no merge; (ii) Precursor Options: corrected; (iii) Charge Options: no correction; (iv) Filter Options: no filter; (v) Process: true; (vi) Default: true; (vii) Associate Chimera: yes. De novo sequencing was performed with Parent Mass Error Tolerance set to 10 ppm. Fragment Mass Error Tolerance was set to 0.15 Da, and Enzyme was set to none. The following variable modifications have been used: Oxidation (M), pyro-Glu from Q (N-term Q), and carbamidomethylation (C). A maximum of 3 variable post-translational modifications (PTMs) were allowed per peptide. Up to 10 de novo sequencing candidates were reported for each identified fragment ion mass spectrum, with their corresponding average local confidence (ALC) score. Because we applied the chimeric spectra option of PEAKS X, two or more TOP10 candidate lists could be assigned to a single fragment ion spectrum. Two tables (“all de novo candidates” and “de novo peptides”) were exported from PEAKS for further analysis.

All de novo sequence candidates were matched against the 6-frame translated human genome (hg38) and the 3-frame translated human transcriptome (ENSEMBL 90) using Peptide-PRISM. Results were filtered to 10% FDR for each category (CDS, UTR5, OffFrame, ncRNA, UTR3, intronic, intergenic). NetMHCpan 4.0 was used to predict binding affinities for all identified HLA-I peptides for all HLA alleles of the corresponding patient. The allele with the minimal rank reported by NetMHCpan was annotated. As per default, we used a cutoff of 0.5% rank for strong binders and 2% rank for weak binders.

Identification of cryptic peptides from the glioblastoma (GBM) data set (18) has been performed in the same way using Peptide-PRISM. Comprehensive results have been published recently (13).

Synthetic peptides were analyzed on an LTQ-Orbitrap Velos Pro (Thermo Scientific) equipped with a PicoView Ion Source (New Objective) and coupled to an EASY-nLC 1000 (Thermo Scientific). Peptides were loaded on capillary columns (PicoFrit, 30 cm x 150 µm ID, New Objective) self-packed with ReproSil-Pur 120 C18-AQ, 1.9 µm (Dr. Maisch) and separated with a 30-minute linear gradient from 3% to 30% acetonitrile and 0.1% formic acid and a flow rate of 500 nl/min. MS scans were acquired in the Orbitrap analyzer with a resolution of 30,000 at m/z 400, MS/MS scans were acquired in the Ion Trap analyzer with normal scan rate using CID fragmentation with 35% normalized collision energy. A TOP10 data-dependent MS/MS method was used; dynamic exclusion was applied with a repeat count of 1 and an exclusion duration of 120 seconds; singly charged precursors were excluded from selection. Minimum signal threshold for precursor selection was set to 20,000. AGC was used with AGC target with a value of 1e6 for MS scans and 1e4 for MS/MS scans. Lock mass option was applied for internal calibration in all runs using background ions from protonated decamethylcyclopentasiloxane (m/z 371.10124).

Statistical analyis

For defining correlations between different IHC markers, the percentages of marker positive cells in neuropathological slides were logit-transformed and plotted by Pearson linear regression using SPSS V26. Differences between two groups were assessed by nonparametric Mann–Whitney U test assuming unequal variances. For comparison of multiple groups, the non-parametric Kruskal–Wallis rang-sum test was used. For differences within a group the two-tailed t test was applied. p < 0.05 was considered statistically significant.